Position in CELC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$41,795,214
+$11,931,363 QoQ
Shares Held
366,175
+22.3% QoQ
Ownership
0.751%
of shares outstanding
% of Portfolio
2.10%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Derivatives in CELC
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$34,242,000
PutShares
300,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Sofinnova Investments, Inc. holds $1,140,503,369 across 48 Biotechnology names. CELC ranks #8 (3.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
598,327 | $113,113,719 | |
| 2 | VERA |
Vera Therapeutics, Inc.
|
2,793,987 | $112,402,097 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
2,113,551 | $81,350,577 | |
| 4 | RARE |
Ultragenyx Pharmaceutical Inc.
|
3,145,888 | $65,906,353 | |
| 5 | RAPP |
Rapport Therapeutics, Inc.
|
1,904,408 | $59,588,926 | |
| 6 | INSM |
INSMED Inc
|
346,075 | $56,590,184 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
781,982 | $44,174,163 | |
| 8 | CELC |
Celcuity Inc.
This page
|
366,175 | $41,795,214 |
All Filings in CELC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $34,242,000 | 300,000 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $41,795,214 | 366,175 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $29,863,851 | 299,417 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $12,516,725 | 253,375 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||